Brimonidine

also known as Brimonidine Tartrate · Alphagan · CD07805/47 · Alphagan-P · Lumify · Brimonidine tartarate · Mirvaso · AGN 190342-LF · +21 more

Small molecule

Developed for: glaucoma · open-angle glaucoma · ocular hypertension · rosacea · presbyopia · ocular hyperemia · diabetic retinopathy · ptosis
+25 more
· age-related macular degeneration · conjunctivitis · dry eye syndrome · hand-foot syndrome · angle-closure glaucoma · borderline glaucoma · capillary malformation · chemotherapy-induced neuropathy · conjunctival disorder · corneal edema · diffuse secondary choroid atrophy · ectropion · entropion · exfoliation syndrome · eye allergy · flushing of ears and somnolence · graft versus host disease · intraoperative floppy iris syndrome · low tension glaucoma · macular degeneration · myopia · retinitis pigmentosa · rhegmatogenous retinal detachment · telangiectasis · vascular disorder
Investigated by: Allergan · Galderma R&D · LENZ Therapeutics, Inc · Alcon Research · Bausch & Lomb Incorporated · ORA, Inc.
+57 more
· Massachusetts Eye and Ear Infirmary · Ocugen · Tarian Pharma · University of Sao Paulo · Corxel Pharmaceuticals · Medical University of Vienna · Optall Vision · Padagis LLC · Uptown Eye Specialists · Wake Forest University Health Sciences · AbbVie · Actavis Inc. · Afyon Kocatepe University Hospital · BCN Peptides · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Biogen · Canadian Glaucoma Clinical Research Council · Carmel Medical Center · Chicago Center for Vision Research · Chittagong Medical College · Credit Valley EyeCare · Denver Health and Hospital Authority · Derm Research, PLLC · Duke University · Eurotrials Brasil Consultores Cientificos Ltda · Eye Therapies, LLC · Fayoum University · Federal University of São Paulo · Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP · Galderma Brasil Ltda. · Heinrich-Heine University, Duesseldorf · Hermann Eye Center · Indiana University · Innovative Medical · Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Istanbul Training and Research Hospital · Kukje Pharma · Laboratorios Sophia S.A de C.V. · Nanduri, Padma, M.D., FACS · Novartis Pharmaceuticals · Prairie Eye Center · Rabin Medical Center · Sengi · Sheba Medical Center · Sun Pharma Advanced Research Company Limited · Sun Yat-sen University · Tecnoquimicas · The Hospital for Sick Children · Tulane University · University Health Network, Toronto · University of California, Los Angeles · University of California, San Francisco · University of Louisville · University of Parma · Watson Laboratories, Inc. · Zagazig University · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Mirvaso	—	2014-02-20	europa.eu ↗
Label expansion	US (FDA)	ALPHAGAN	—	2001-12-20	fda.gov ↗
Approved	US (FDA)	ALPHAGAN	—	1996-09-06	fda.gov ↗

Trials 111 · started per year

today

US approved 1996

EU approved 2014

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06730516	Jun → Sep 2024	glaucoma	Zagazig University	Completed	No outcome recorded
Phase 0	NCT03825081	Jan → Sep 2019	presbyopia	Massachusetts Eye and Ear Infirmary	Unknown	No outcome recorded
Phase 0	NCT03497442	Jul 2018 → Mar 2019	alcohol-related disorders, flushing of ears and somnolence	University of California, San Francisco	Completed	No outcome recorded
Phase 18 trials
Phase 1	NCT06270030	Mar → Apr 2024	presbyopia	Corxel Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT05936489	Jul → Oct 2023	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 1	NCT05006911	Aug → Sep 2021	presbyopia	Optall Vision	Unknown	No outcome recorded
Phase 1	NCT05006898	Jun → Jul 2020	presbyopia	Optall Vision	Completed	No outcome recorded
Phase 1	NCT02967614	Dec 2016 → Dec 2017	glaucoma, ocular hypertension	Kukje Pharma	Completed	No outcome recorded
Phase 1	NCT03139708	Sep 2016 → Oct 2017	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT02039765	Feb → Mar 2014	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 1	NCT01229410	Dec 2010 → May 2011	—	Allergan	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00661479	Jul 2008 → Dec 2009	retinitis pigmentosa	Allergan	Completed	No outcome recorded
Phase 227 trials
Phase 2	NCT07457671	Mar 2026 → Mar 2027 expected	hand-foot syndrome	Tarian Pharma	Not yet recruiting	No outcome recorded
Phase 2	NCT07082764	Sep 2025 → Sep 2026 expected	chemotherapy-induced neuropathy	Tarian Pharma	Not yet recruiting	No outcome recorded
Phase 2	NCT06948357	Mar → Sep 2025 overdue	presbyopia	Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Recruiting	No outcome recorded
Phase 2	NCT06818058	Jan 2025 → Sep 2026 expected	—	Tarian Pharma	Recruiting	No outcome recorded
Phase 2	NCT06365853	Jul 2024 → Jun 2026 overdue	ovarian cancer	AbbVie	Recruiting	No outcome recorded
Phase 2	NCT05431543	Aug → Dec 2022	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 2	NCT05294328	May → Aug 2022	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 2	NCT03760185	Jan 2019 → Sep 2020	intraoperative floppy iris syndrome	Denver Health and Hospital Authority	Completed	No outcome recorded
Phase 2	NCT04205201	Jun 2018 → Sep 2019	—	Chittagong Medical College	Completed	No outcome recorded
Phase 2	NCT03418727	Sep 2017 → Mar 2018	dry eye syndrome	Ocugen	Completed	No outcome recorded
Phase 2	NCT03173365	Jul 2017 → Dec 2018	hand-foot syndrome	Heinrich-Heine University, Duesseldorf	Terminated	No outcome recorded
Phase 2	NCT02214680	Oct 2015 → Aug 2016	—	Carmel Medical Center	Unknown	No outcome recorded
Phase 2	NCT02087085	May 2014 → Mar 2018	age-related macular degeneration, diffuse secondary choroid atrophy	Allergan	Terminated	No outcome recorded
Phase 2	NCT02300129	Apr → Jun 2014	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT01675609	Aug → Oct 2012	ocular hyperemia	Eye Therapies, LLC	Completed	No outcome recorded
Phase 2	NCT01426867	Sep → Nov 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01345448	Apr → Jul 2011	glaucoma	Nanduri, Padma, M.D., FACS	Unknown	No outcome recorded
Phase 2	NCT01174030	Aug → Dec 2010	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT01080209	Feb 2010 → Feb 2014	—	Allergan	Completed	No outcome recorded
Phase 2	NCT00972374	Nov 2009 → Oct 2010	rhegmatogenous retinal detachment	Allergan	Completed	No outcome recorded
Phase 2	NCT00989014	Sep → Nov 2009	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT00693485	Sep 2008 → Jan 2011	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 2	NCT00864838	Jun 2008 → Feb 2009	age-related macular degeneration, diabetic retinopathy	University of Sao Paulo	Completed	No outcome recorded
Phase 2	NCT00658619	May 2008 → Jun 2010	macular degeneration	Allergan	Completed	No outcome recorded
Phase 2	NCT00697541	May → Jun 2008	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT00317577	Dec 1998 → May 2004	open-angle glaucoma	Chicago Center for Vision Research	Completed	No outcome recorded
Phase 2	NCT00804921	—	diabetic retinopathy, macular retinal edema	University of Sao Paulo	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT01726075	Feb 2013 → Nov 2015	diabetic retinopathy	BCN Peptides	Completed	No outcome recorded
Phase 329 trials
Phase 3	NCT06045299	Sep 2023 → Aug 2024	presbyopia	Corxel Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT05815758	Apr → Sep 2023	eye allergy	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05728944	Mar → Dec 2023	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 3	NCT05753189	Feb 2023 → Feb 2024	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 3	NCT05656027	Dec 2022 → Dec 2023	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 3	NCT05591755	Nov 2022 → Aug 2023	conjunctivitis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05579730	Oct 2022 → Jul 2023	conjunctivitis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05360784	May → Nov 2022	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT04944290	May 2021 → Mar 2022	ocular hypertension, open-angle glaucoma	Padagis LLC	Completed	No outcome recorded
Phase 3	NCT03591874	Dec 2018 → Apr 2020	eye adnexa disorder, graft versus host disease	Ocugen	Terminated	No outcome recorded
Phase 3	NCT03785340	Dec 2018 → Feb 2019	dry eye syndrome	Ocugen	Completed	No outcome recorded
Phase 3	NCT03450629	Sep 2018 → Dec 2020	ocular hypertension, open-angle glaucoma	Sun Pharma Advanced Research Company Limited	Completed	No outcome recorded
Phase 3	NCT02764411	Jun 2016 → Oct 2018	capillary malformation	The Hospital for Sick Children	Terminated	No outcome recorded
Phase 3	NCT02385240	Mar → Dec 2015	rosacea	Padagis LLC	Completed	No outcome recorded
Phase 3	NCT02289352	Jul → Dec 2014	rosacea	Actavis Inc.	Completed	No outcome recorded
Phase 3	NCT01959243	Feb → Apr 2014	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT01959230	Nov → Dec 2013	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT01885000	Jul → Nov 2013	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01284166	Jul 2013 → May 2014	glaucoma, ocular hypertension	Allergan	Withdrawn	No outcome recorded
Phase 3	NCT01659853	Sep → Dec 2012	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01355458	May → Sep 2011	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01355471	May → Nov 2011	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01318733	Mar 2011 → Jun 2012	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01297920	Mar 2011 → Jun 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00800423	Jan 2009 → Jan 2010	corneal edema	Rabin Medical Center	Unknown	No outcome recorded
Phase 3	NCT00168363	Jan 2005 → Aug 2006	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00652483	May → Dec 2003	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00061529	Jan 2003 → Jul 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01882712	? → Sep 2015	—	Galderma R&D	Withdrawn	No outcome recorded

Phase 432 trials
Phase 4	NCT07390578	Dec 2026 → Aug 2027 expected	ptosis	Duke University	Not yet recruiting	No outcome recorded
Phase 4	NCT04007276	Nov 2026 → Jun 2031 expected	open-angle glaucoma, ptosis	Tulane University	Not yet recruiting	No outcome recorded
Phase 4	NCT07690397	Jun 2026 → Jul 2027 expected	ocular hypertension, open-angle glaucoma	Tecnoquimicas	Active not recruiting	No outcome recorded
Phase 4	NCT07209410	Nov 2025 → Dec 2026 expected	glaucoma	Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,	Recruiting	No outcome recorded
Phase 4	NCT06883123	May 2025 → Apr 2026 overdue	open-angle glaucoma	Prairie Eye Center	Recruiting	No outcome recorded
Phase 4	NCT07431476	May → Aug 2025	rosacea	Istanbul Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT05480098	May 2022 → May 2024	ectropion, entropion, ptosis	University of Louisville	Withdrawn	No outcome recorded
Phase 4	NCT04702789	Oct 2021 → Nov 2023	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Terminated	No outcome recorded
Phase 4	NCT06761313	Mar 2021 → Dec 2024 overdue	glaucoma	Federal University of São Paulo	Active not recruiting	No outcome recorded
Phase 4	NCT05474716	May 2020 → Dec 2021	ocular vascular disorder, open-angle glaucoma	Fayoum University	Completed	No outcome recorded
Phase 4	NCT03959176	Jul 2019	ocular hypertension	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT03150160	Sep → Dec 2017	glaucoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02863705	Jul 2016 → Jul 2018	low tension glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02730871	Jun 2016 → Jul 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 4	NCT02856919	Jun 2016 → Feb 2017	—	Galderma Brasil Ltda.	Completed	No outcome recorded
Phase 4	NCT02818816	Feb 2016 → Jan 2017	prostate cancer	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT02568111	Feb → Aug 2016	relapsing-remitting multiple sclerosis	Biogen	Withdrawn	No outcome recorded
Phase 4	NCT02616250	Dec 2015 → Sep 2016	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 4	NCT02419508	Aug 2015 → Feb 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT02249065	Sep 2014 → Aug 2015	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 4	NCT02147691	May 2014 → Jan 2015	rosacea	Derm Research, PLLC	Completed	No outcome recorded
Phase 4	NCT03966560	Jan 2014 → Jan 2015	open-angle glaucoma	Afyon Kocatepe University Hospital	Completed	No outcome recorded
Phase 4	NCT01535768	Feb 2012 → Jun 2018	glaucoma	Credit Valley EyeCare	Unknown	No outcome recorded
Phase 4	NCT02003534	Jul 2010 → Feb 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01151904	Nov 2009 → Feb 2012	angle-closure glaucoma	Allergan	Terminated	No outcome recorded
Phase 4	NCT00869141	Mar 2009 → Mar 2013	glaucoma	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00800540	Feb 2009 → Jan 2012	open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00457795	Dec 2006 → Feb 2009	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00440141	Jul 2006 → Mar 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00312416	Feb → Dec 2004	—	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00466479	Aug 1999 → Oct 2002	glaucoma	University of Parma	Completed	No outcome recorded
Phase 4	NCT00348400	—	glaucoma	Innovative Medical	Completed	No outcome recorded

Phase not applicable10 trials
—	NCT04683159	Feb → Jul 2021	pterygium	Uptown Eye Specialists	Unknown	No outcome recorded
—	NCT04296916	Apr 2020 → Oct 2024	borderline glaucoma, myopia	Sun Yat-sen University	Unknown	No outcome recorded
—	NCT04633954	Jun → Aug 2019	cataract, conjunctival disorder	Uptown Eye Specialists	Completed	No outcome recorded
—	NCT03220490	Nov 2017 → Nov 2022	glaucoma	Sheba Medical Center	Unknown	No outcome recorded
—	NCT01105065	Mar 2010 → Sep 2012	glaucoma	Massachusetts Eye and Ear Infirmary	Completed	No outcome recorded
—	NCT00824824	Jan 2009 → Aug 2012	glaucoma	Massachusetts Eye and Ear Infirmary	Completed	No outcome recorded
—	NCT00275756	Sep 2008 → Nov 2014	glaucoma	Medical University of Vienna	Withdrawn	No outcome recorded
—	NCT00435058	Sep 2005 → Apr 2006	glaucoma	University of Sao Paulo	Completed	No outcome recorded
—	NCT00352807	Feb → Dec 2005	cataract	Indiana University	Completed	No outcome recorded
—	NCT00121147	Sep 2003 → Oct 2005	exfoliation syndrome, ocular hypertension, open-angle glaucoma	Hermann Eye Center	Completed	No outcome recorded

Also used as a comparator or background therapy in 52 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT01144494 Comparator	Aug 2010 → Oct 2011	ocular hypertension	University of Nebraska	Completed	No outcome recorded
Phase 12 trials
Phase 1	NCT05001243 Comparator	Aug 2021	presbyopia	Optall Vision	Unknown	No outcome recorded
Phase 1	NCT01687426 Comparator	Sep → Dec 2012	open-angle glaucoma	Eye Therapies, LLC	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT02975557 Comparator	May 2016 → Apr 2017	dry eye syndrome, graft versus host disease	Sandeep Jain, MD	Terminated	No outcome recorded
Phase 26 trials
Phase 2	NCT06996236 Comparator	Jul 2025 → Jul 2026 overdue	myopia	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Not yet recruiting	No outcome recorded
Phase 2	NCT01863953 Comparator	Jun → Dec 2013	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT01275105 Comparator	Jan → Mar 2011	eye allergy	Eye Therapies, LLC	Completed	No outcome recorded
Phase 2	NCT01887223 Comparator	May 2010 → Jun 2011	open-angle glaucoma	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 2	NCT00961649 Comparator	Oct 2009 → Feb 2010	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 2	NCT01062971 Comparator	Feb 2006 → Aug 2007	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Completed	No outcome recorded

Phase 313 trials
Phase 3	NCT06803654 Comparator	May → Jun 2025	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05270863 Comparator	Mar 2022 → Mar 2023	presbyopia	Visus Therapeutics	Completed	No outcome recorded
Phase 3	NCT02339584 Comparator	Apr 2015 → Nov 2016	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01789775 Comparator	Dec 2012 → Oct 2013	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01309204 Comparator	May 2011 → Jan 2013	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01310777 Comparator	May 2011 → Jan 2013	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01241240 Comparator	Mar 2011 → Sep 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT01297517 Comparator	Feb 2011 → Mar 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01217606 Comparator	Jan 2011 → Sep 2014	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 3	NCT01216943 Background	Nov 2010 → Aug 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01004900 Comparator	Jun 2009 → Mar 2011	glaucoma	Singapore Eye Research Institute	Unknown	No outcome recorded
Phase 3	NCT00651612 Comparator	Nov 2005 → Jan 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00652106 Comparator	Jun 2003 → Mar 2004	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded

Phase 419 trials
Phase 4	NCT06449352 Comparator	Jun 2024 → Sep 2025	low tension glaucoma	Westlake Eye Specialists	Completed	No outcome recorded
Phase 4	NCT06369077 Comparator	Apr → Jul 2024	open-angle glaucoma	CT Glaucoma Associates	Terminated	No outcome recorded
Phase 4	NCT06078592 Comparator	Oct 2021 → Dec 2022	glaucoma, ocular hypertension	CHA University	Completed	No outcome recorded
Phase 4	NCT03782701 Comparator	Jun 2019 → Apr 2020	ptosis	University of Miami	Completed	No outcome recorded
Phase 4	NCT04647461 Comparator	Mar 2019 → Jan 2021	glaucoma, ocular hypertension	CHA University	Unknown	No outcome recorded
Phase 4	NCT03323164 Comparator	Jul 2017 → Dec 2018	low tension glaucoma	Wills Eye	Completed	No outcome recorded
Phase 4	NCT03192826 Comparator	Jun 2016 → Jul 2017	lens disorder, ocular hypertension	University Hospital of Patras	Completed	No outcome recorded
Phase 4	NCT03048058 Background	May 2016 → Jun 2017	rosacea	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT02761174 Comparator	Mar → Jul 2016	telangiectasis	Merete Haedersdal	Completed	No outcome recorded
Phase 4	NCT01525173 Comparator	Jan → Oct 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01446497 Comparator	Oct 2010 → Aug 2011	low tension glaucoma	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT01170884 Comparator	Dec 2009 → Sep 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00972257 Comparator	Jan → Sep 2009	open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00811564 Comparator	Dec 2008 → Jan 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00811850 Comparator	Dec 2008 → Dec 2009	glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00735449 Comparator	Jul 2008 → Dec 2009	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00698945 Comparator	Jun → Nov 2008	ocular hypertension, open-angle glaucoma	Bp Consulting, Inc	Completed	No outcome recorded
Phase 4	NCT00675207 Comparator	Jan 2006 → Jul 2007	ocular hypertension, open-angle glaucoma	Northwestern Ophthalmic Institute S.C.	Completed	No outcome recorded
Phase 4	NCT00347035 Background	—	glaucoma	Federal University of São Paulo	Terminated	No outcome recorded

Phase not applicable10 trials
—	NCT04523844 Comparator	May → Jul 2020	ocular hypertension	General Hospital of Athens Elpis	Completed	No outcome recorded
—	NCT03494257 Comparator	Sep 2017 → Mar 2018	cataract	University Hospital of Patras	Completed	No outcome recorded
—	NCT03513172 Comparator	Dec 2016 → Jul 2017	ocular hypertension	University of Toronto	Completed	No outcome recorded
—	NCT03508869 Comparator	Sep 2016 → Sep 2017	rosacea	Skin Laser & Surgery Specialists	Terminated	No outcome recorded
—	NCT02140450 Comparator	Feb 2012 → Jan 2014	—	Mashhad University of Medical Sciences	Completed	No outcome recorded
—	NCT01201551 Comparator	Jun 2011 → Nov 2013	vascular disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
—	NCT01229462 Comparator	Oct 2010 → Sep 2011	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
—	NCT00712777 Comparator	Mar 2008 → Nov 2014	—	Medical University of Vienna	Withdrawn	No outcome recorded
—	NCT00402493 Comparator	Dec 2006 → Mar 2008	glaucoma, ocular hypertension	Philadelphia Eye Associates	Completed	No outcome recorded
—	NCT00567411 Comparator	Aug 2006 → Jun 2009	ocular hypertension, open-angle glaucoma	Walter Reed Army Medical Center	Unknown	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2022-04-14	Novartis Pharmaceuticals	Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio novartis.com ↗

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 169 sources stand behind the page.

Field	Value	Cited text
Known as	brimonidine	“Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.” NCT03508869 ↗ 136 “a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID)” NCT01535768 ↗ “Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System” NCT01080209 ↗ “Each patient will receive the active TAR-0520 gel containing 1.5% of Brimonidine tartrate.” NCT07457671 ↗ “Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA)” NCT06803654 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗ “Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(without preservative)” NCT06078592 ↗ “Compare also to timolol/brimonidine/dorzolamide/bimatoprost” NCT06369077 ↗ “Brimonidine was instilled in the other eye.” NCT05006898 ↗ “brinzolamide and brimonidine tartrate” NCT06883123 ↗ “Brimonidine , Timolol” NCT02967614 ↗ “Brimonidine” NCT04205201 ↗ NCT01241240 ↗ NCT00661479 ↗ NCT05431543 ↗ NCT01675609 ↗ NCT05591755 ↗ NCT01309204 ↗ NCT01105065 ↗ NCT01310777 ↗ NCT01345448 ↗ NCT00824824 ↗ NCT00804921 ↗ NCT03494257 ↗ NCT07082764 ↗ NCT02003534 ↗ NCT03966560 ↗ NCT00712777 ↗ NCT05656027 ↗ NCT00697541 ↗ NCT06948357 ↗ NCT05001243 ↗ NCT00800540 ↗ NCT00275756 ↗ NCT05294328 ↗ NCT02140450 ↗ NCT01446497 ↗ NCT03048058 ↗ NCT01726075 ↗ NCT03959176 ↗ NCT01170884 ↗ NCT01687426 ↗ NCT01525173 ↗ NCT00652106 ↗ NCT00869141 ↗ NCT00347035 ↗ NCT07209410 ↗ NCT06730516 ↗ NCT00348400 ↗ NCT06818058 ↗ NCT02385240 ↗ NCT02289352 ↗ NCT07390578 ↗ NCT05006911 ↗ NCT01144494 ↗ NCT02419508 ↗ NCT01284166 ↗ NCT02761174 ↗ NCT00811850 ↗ NCT00457795 ↗ NCT02975557 ↗ NCT00972257 ↗ NCT01297517 ↗ NCT07690397 ↗ NCT00317577 ↗ NCT03192826 ↗ NCT07431476 ↗ NCT04683159 ↗ NCT05936489 ↗ NCT00735449 ↗ NCT00466479 ↗ NCT01217606 ↗ NCT03173365 ↗ NCT02214680 ↗ NCT00435058 ↗ NCT04007276 ↗ NCT02616250 ↗ NCT04523844 ↗ NCT02147691 ↗ NCT00440141 ↗ NCT06270030 ↗ NCT01275105 ↗ NCT06045299 ↗ NCT00652483 ↗ NCT02764411 ↗ NCT00961649 ↗ NCT03150160 ↗ NCT02087085 ↗ NCT06996236 ↗ NCT03825081 ↗ NCT01151904 ↗ NCT05480098 ↗ NCT02730871 ↗ NCT00972374 ↗ NCT03591874 ↗ NCT00675207 ↗ NCT05474716 ↗ NCT00352807 ↗ NCT01426867 ↗ NCT01229462 ↗ NCT01229410 ↗ NCT02249065 ↗ NCT02339584 ↗ NCT00312416 ↗ NCT03220490 ↗ NCT03450629 ↗ NCT00168363 ↗ NCT04944290 ↗ NCT00651612 ↗ NCT00567411 ↗ NCT05815758 ↗ NCT05728944 ↗ NCT01201551 ↗ NCT00061529 ↗ NCT00800423 ↗ NCT02856919 ↗ NCT00693485 ↗ NCT01297920 ↗ NCT04633954 ↗ NCT01959230 ↗ NCT03513172 ↗ NCT06449352 ↗ NCT00402493 ↗ NCT00864838 ↗ NCT04702789 ↗ NCT00658619 ↗ NCT01216943 ↗ NCT05753189 ↗ NCT03782701 ↗ NCT01863953 ↗ NCT01004900 ↗ NCT01885000 ↗ NCT05579730 ↗ NCT03418727 ↗ NCT01062971 ↗ NCT02039765 ↗ NCT00811564 ↗
Known as	AGN 190342-LF	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	AGN-190342 FREE BASE	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Alphagan	“first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker).” NCT03220490 ↗ 8 “In one group of 10 participants the left eyes will receive Alphagan prior to Tropicamide/phenylephrine.” NCT03139708 ↗ “Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye” NCT00712777 ↗ “Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®” NCT00275756 ↗ “Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT” NCT00567411 ↗ “Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops” NCT00402493 ↗ “alphagan 0.2% or alphagan-P 0.15% will be added.” NCT04296916 ↗ “Alphagan” NCT01887223 ↗ NCT00698945 ↗
Known as	ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd	“ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd” NCT03192826 ↗
Known as	Alphagan-P	“OBJECTIVE: To compare the safety and intraocular pressure (IOP)-lowering effects of brimonidine-purite 0.1% with the marketed formulation of brimonidine-purite 0.15% (Alphagan...” PMID 18534052 ↗ Jun 2008 3 “Patients will be randomly assigned based on a pre-determined allocation sequence to receive topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc) during either the...” NCT03513172 ↗ “The purpose of this study is to test the use of a well-known eye medication (normally for treating glaucoma) called Brimonidine tartrate 0.15% (or Alphagan-P) in patients...” NCT04633954 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗
Known as	Brimo DDS	“Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant” PMID 32134802 ↗ Jan 2021
Known as	Brimonidina	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Brimonidine d-tartrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Brimonidine Drug Delivery System	“Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant” PMID 32134802 ↗ Jan 2021
Known as	brimonidine purite	“To evaluate the efficacy and tolerability of brimonidine purite 0.1% in comparison to brinzolamide 1% when used as adjunctive therapy to latanoprost 0.005% in patients with...” PMID 18402717 ↗ Apr 2008
Known as	Brimonidine tartarate	“The control group (Group II) is going to be treated with a combination of three separated eyedrops: Brimonidine Tartarate 0.2%,Timolol Maleate 0.5%, Bimatoprost 0.03%.” NCT06761313 ↗ 1 “Drug: Brimonidine tartarate” NCT00864838 ↗
Known as	Brimonidine Tartrate	“The combination of the eye drops Bimatoprost 0.3%, Timolol Maleate 0.5%, and Brimonidine Tartrate 0.2% in separate vials is traditionally used in patients with difficult...” NCT06761313 ↗ 30 “The purpose of this study is to test the use of a well-known eye medication (normally for treating glaucoma) called Brimonidine tartrate 0.15% (or Alphagan-P) in patients...” NCT04633954 ↗ “The purpose of this study is to evaluate the safety and efficacy of brimonidine tartrate 0.025% ophthalmic solution used four times daily in a population of adult and geriatric subjects” NCT01675609 ↗ “the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.” PMID 21257146 ↗ Jan 2011 “One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.” NCT01229462 ↗ “Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye.” NCT04683159 ↗ “Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System” NCT01080209 ↗ “0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.” NCT02003534 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗ “Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.” NCT01726075 ↗ “brimonidine tartrate ophthalmic solution 0.2% in each eye” NCT01863953 ↗ “Brimonidine tartrate ophthalmic solution 0.025%” NCT03782701 ↗ “Brimonidine tartrate ophthalmic solution, 0.2%” NCT00961649 ↗ “Brimonidine Tartrate Ophthalmic Solution” NCT00061529 ↗ “400 µg Brimonidine Tartrate Implant” NCT01229410 ↗ “Brimonidine Tartrate 0.2% drops” NCT00800423 ↗ “Drug: Brimonidine tartrate” NCT02039765 ↗ “Drug: Brimonidine Tartrate” NCT03591874 ↗ “Drug: Brimonidine Tartrate” NCT03173365 ↗ NCT03785340 ↗ NCT02568111 ↗ NCT06365853 ↗ NCT05270863 ↗ NCT02863705 ↗ NCT04647461 ↗ NCT03497442 ↗ NCT05360784 ↗ NCT03760185 ↗ NCT02818816 ↗ NCT03323164 ↗ NCT01959243 ↗
Known as	Brimonidine tartrate component of combigan	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Brimonidine tartrate component of simbrinza	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Brimonidine Tartrate PS DDS	“Brimonidine Tartrate PS DDS®” NCT01229410 ↗
Known as	Bromoxidine tartrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Brymont	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	BTOS-PF 0.025%	“A BAK-free formulation of LUMIFY 0.025% (BTOS-PF 0.025%) could offer a solution for BAK-sensitive patients.” PMID 40711722 ↗ Jul 2025
Known as	Cd-07805	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	CD07805/47	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01174030 ↗ 8 NCT01318733 ↗ NCT01882712 ↗ NCT01659853 ↗ NCT01789775 ↗ NCT01355458 ↗ NCT00989014 ↗ NCT02300129 ↗ NCT01355471 ↗
Known as	Lumify	“Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours...” NCT05360784 ↗ 2 “Patients experiencing hyperemia greater than grade 2 on Efron scale will receive brimonidine tartrate (Lumify).” NCT07209410 ↗ “Brimonidine 0.025% (Lumify)” NCT07390578 ↗
Known as	Lumify preservative free	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Mirvaso	“Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA)” NCT02289352 ↗ 1 NCT03508869 ↗
Known as	NSC-318825	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	OCU-300	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	Qoliana	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	UK-14304	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	UK-14304-18	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Known as	UK-1430418 FREE BASE	ChEMBL registry synonym — accepted as the source's own label CHEMBL844 ↗
Action	Activate	“Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗
Modality	Small molecule	— CHEMBL844 ↗
Route	Topical	“dose: 1 drop in one eye twice daily for two weeks” NCT00275756 ↗